ABIOMED Stock Price, News & Analysis (NASDAQ:ABMD)

$199.74 0.88 (0.44 %)
(As of 11/24/2017 02:16 AM ET)
Previous Close$198.86
Today's Range$198.56 - $199.98
52-Week Range$103.53 - $200.00
Volume85,790 shs
Average Volume336,839 shs
Market Capitalization$8.79 billion
P/E Ratio127.47
Dividend YieldN/A
Beta0.23

About ABIOMED (NASDAQ:ABMD)

ABIOMED logoABIOMED, Inc. is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart. The Company's product portfolio includes the Impella 2.5, Impella CP, Impella RP, Impella LD, Impella 5.0 and AB5000. The Company's products are used in the cardiac catheterization lab (cath lab), by interventional cardiologists, the electrophysiology lab, the hybrid lab and in the heart surgery suite by heart surgeons.

Receive ABMD News and Ratings via Email

Sign-up to receive the latest news and ratings for ABMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:ABMD
CUSIP00365410
Phone978-646-1400

Debt

Debt-to-Equity Ratio0.02%
Current Ratio5.84%
Quick Ratio5.20%

Price-To-Earnings

Trailing P/E Ratio127.47
Forward P/E Ratio83.92
P/E Growth2.65

Sales & Book Value

Annual Sales$445.30 million
Price / Sales19.83
Cash Flow$1.35 per share
Price / Cash148.47
Book Value$13.68 per share
Price / Book14.60

Profitability

Trailing EPS$2.03
Net Income$52.11 million
Net Margins18.27%
Return on Equity13.89%
Return on Assets11.83%

Miscellaneous

Employees908
Outstanding Shares44,220,000

Frequently Asked Questions for ABIOMED (NASDAQ:ABMD)

What is ABIOMED's stock symbol?

ABIOMED trades on the NASDAQ under the ticker symbol "ABMD."

How were ABIOMED's earnings last quarter?

ABIOMED, Inc. (NASDAQ:ABMD) posted its earnings results on Thursday, October, 26th. The medical equipment provider reported $0.54 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.38 by $0.16. The medical equipment provider earned $132.80 million during the quarter, compared to analyst estimates of $131.18 million. ABIOMED had a return on equity of 13.89% and a net margin of 18.27%. The company's quarterly revenue was up 28.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.20 EPS. View ABIOMED's Earnings History.

When will ABIOMED make its next earnings announcement?

ABIOMED is scheduled to release their next quarterly earnings announcement on Wednesday, January, 24th 2018. View Earnings Estimates for ABIOMED.

Where is ABIOMED's stock going? Where will ABIOMED's stock price be in 2017?

8 brokers have issued twelve-month price targets for ABIOMED's shares. Their forecasts range from $140.00 to $208.00. On average, they expect ABIOMED's stock price to reach $180.43 in the next twelve months. View Analyst Ratings for ABIOMED.

Who are some of ABIOMED's key competitors?

Who are ABIOMED's key executives?

ABIOMED's management team includes the folowing people:

  • Michael R. Minogue, Chairman of the Board, President, Chief Executive Officer (Age 50)
  • Ian McLeod, Principal Financial Officer, Principal Accounting Officer, Vice President, Controller
  • David M. Weber, Chief Operating Officer (Age 55)
  • William J. Bolt, Senior Vice President, Global Quality, Regulatory and Clinical Operations (Age 65)
  • Andrew J. Greenfield, Vice President, General Manager - Global Marketing (Age 44)
  • Michael G. Howley, Vice President, General Manager - Global Sales and Marketing (Age 53)
  • Dorothy E. Puhy, Lead Independent Director (Age 65)
  • Jeannine M. Rivet, Independent Director (Age 69)
  • Eric A. Rose M.D., Independent Director (Age 66)
  • Martin P. Sutter, Independent Director (Age 62)

Who owns ABIOMED stock?

ABIOMED's stock is owned by a number of of retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (4.48%), Janus Henderson Group PLC (2.44%), Bank of New York Mellon Corp (1.60%), Scout Investments Inc. (1,248,188.60%), Jackson Square Partners LLC (1.23%) and American Century Companies Inc. (1.10%). Company insiders that own ABIOMED stock include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Henri A Termeer, Michael G Howley, Michael R Minogue, Paul Thomas and William J Bolt. View Institutional Ownership Trends for ABIOMED.

Who sold ABIOMED stock? Who is selling ABIOMED stock?

ABIOMED's stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, Sectoral Asset Management Inc, Macquarie Group Ltd., Frontier Capital Management Co. LLC, Bank of New York Mellon Corp, Comerica Bank, Rockefeller Financial Services Inc. and Los Angeles Capital Management & Equity Research Inc.. Company insiders that have sold ABIOMED company stock in the last year include Andrew J Greenfield, David M Weber, Dorothy E Puhy, Eric A Md Rose, Michael G Howley and Paul Thomas. View Insider Buying and Selling for ABIOMED.

Who bought ABIOMED stock? Who is buying ABIOMED stock?

ABIOMED's stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Wells Fargo & Company MN, American Century Companies Inc., Hermes Investment Management Ltd., Strs Ohio, Country Trust Bank, Perceptive Advisors LLC and Alyeska Investment Group L.P.. View Insider Buying and Selling for ABIOMED.

How do I buy ABIOMED stock?

Shares of ABIOMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ABIOMED's stock price today?

One share of ABIOMED stock can currently be purchased for approximately $199.74.

How big of a company is ABIOMED?

ABIOMED has a market capitalization of $8.79 billion and generates $445.30 million in revenue each year. The medical equipment provider earns $52.11 million in net income (profit) each year or $2.03 on an earnings per share basis. ABIOMED employs 908 workers across the globe.

How can I contact ABIOMED?

ABIOMED's mailing address is 22 CHERRY HILL DR, DANVERS MA, 01923. The medical equipment provider can be reached via phone at 978-646-1400 or via email at [email protected]


MarketBeat Community Rating for ABIOMED (ABMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  281 (Vote Outperform)
Underperform Votes:  200 (Vote Underperform)
Total Votes:  481
MarketBeat's community ratings are surveys of what our community members think about ABIOMED and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for ABIOMED (NASDAQ:ABMD)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyHoldBuyBuy
Consensus Rating Score: 2.642.452.642.75
Ratings Breakdown: 0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
4 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $185.38$178.25$156.63$141.68
Price Target Upside: 5.69% downside4.01% upside6.06% upside14.81% upside

Consensus Price Target History for ABIOMED (NASDAQ:ABMD)

Price Target History for ABIOMED (NASDAQ:ABMD)

Analysts' Ratings History for ABIOMED (NASDAQ:ABMD)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017SunTrust Banks, Inc.Reiterated RatingBuy$195.00N/AView Rating Details
10/29/2017BTIG ResearchReiterated RatingHoldN/AView Rating Details
10/26/2017Piper Jaffray CompaniesBoost Price TargetOverweight$200.00N/AView Rating Details
10/12/2017Leerink SwannReiterated RatingOutperform$180.00 -> $200.00N/AView Rating Details
9/29/2017Jefferies Group LLCBoost Price TargetBuy$175.00 -> $208.00HighView Rating Details
7/10/2017Morgan StanleyReiterated RatingEqual Weight$135.00 -> $140.00LowView Rating Details
6/8/2017William BlairReiterated RatingOutperform -> OutperformLowView Rating Details
12/6/2016GuggenheimInitiated CoverageBuy$150.00N/AView Rating Details
4/10/2016Benchmark Co.Reiterated RatingBuy$145.00N/AView Rating Details
(Data available from 11/25/2015 forward)

Earnings

Earnings History and Estimates Chart for ABIOMED (NASDAQ:ABMD)

Earnings by Quarter for ABIOMED (NASDAQ:ABMD)

Earnings History by Quarter for ABIOMED (NASDAQ ABMD)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/24/2018$0.50N/AView Earnings Details
10/26/2017Q2 2018$0.38$0.54$131.18 million$132.80 millionViewN/AView Earnings Details
7/27/2017Q1 2018$0.42$0.45$130.83 million$132.47 millionViewN/AView Earnings Details
5/4/2017Q4 2017$0.33$0.33$122.82 million$124.68 millionViewListenView Earnings Details
1/26/2017Q317$0.29$0.34$112.71 million$114.70 millionViewListenView Earnings Details
10/27/2016Q217$0.24$0.20$103.16 million$103.00 millionViewListenView Earnings Details
7/28/2016Q117$0.23$0.29$97.23 million$103.00 millionViewListenView Earnings Details
5/3/2016Q416$0.19$0.24$90.52 million$94.00 millionViewN/AView Earnings Details
2/4/2016Q316$0.15$0.23$80.04 million$85.80 millionViewListenView Earnings Details
10/29/2015Q2$0.13$0.17$74.56 million$76.30 millionViewListenView Earnings Details
8/4/2015Q116$0.08$0.20$66.27 million$73.40 millionViewN/AView Earnings Details
5/5/2015Q415$0.12$0.28$62.55 million$67.60 millionViewN/AView Earnings Details
1/27/2015Q315$0.03$0.30$53.20 million$62.00 millionViewN/AView Earnings Details
10/30/2014Q215$0.02$0.09$48.80 million$51.80 millionViewN/AView Earnings Details
7/31/2014Q115$0.02($0.04)$297.10 million$48.80 millionViewN/AView Earnings Details
5/1/2014Q414$0.09$0.09$50.93 million$50.40 millionViewN/AView Earnings Details
1/31/2014Q314$0.05$0.11$46.00 million$46.20 millionViewN/AView Earnings Details
11/6/2013Q214$0.03$0.03$43.75 million$44.30 millionViewN/AView Earnings Details
8/1/2013Q1 2014$0.06($0.04)$42.93 million$42.70 millionViewN/AView Earnings Details
5/2/2013Q4 2013$0.08$0.09$41.87 million$43.70 millionViewN/AView Earnings Details
2/6/2013Q3 2013$0.07$0.07$38.04 million$38.30 millionViewN/AView Earnings Details
11/1/2012Q213$0.05$0.20$37.47 million$37.40 millionViewN/AView Earnings Details
8/2/2012$0.10$0.16ViewN/AView Earnings Details
5/16/2012$0.07$0.07ViewN/AView Earnings Details
2/3/2012($0.01)$0.07ViewN/AView Earnings Details
11/3/2011($0.09)$0.02ViewN/AView Earnings Details
8/4/2011($0.06)($0.03)ViewN/AView Earnings Details
5/18/2011($0.04)($0.05)ViewN/AView Earnings Details
2/3/2011($0.09)($0.02)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ABIOMED (NASDAQ:ABMD)
2017 EPS Consensus Estimate: $1.09
2018 EPS Consensus Estimate: $1.82
2019 EPS Consensus Estimate: $2.47
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20176$0.20$0.29$0.24
Q2 20173$0.22$0.24$0.23
Q3 20173$0.29$0.31$0.30
Q4 20172$0.32$0.32$0.32
Q1 20183$0.40$0.43$0.41
Q2 20183$0.32$0.38$0.35
Q3 20183$0.46$0.58$0.50
Q4 20183$0.51$0.66$0.56
Q1 20192$0.58$0.63$0.61
Q2 20191$0.51$0.51$0.51
Q3 20191$0.62$0.62$0.62
Q4 20192$0.65$0.82$0.74
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ABIOMED (NASDAQ:ABMD)

No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ABIOMED (NASDAQ ABMD)

Insider Ownership Percentage: 7.00%
Institutional Ownership Percentage: 90.74%
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)
Insider Trades by Quarter for ABIOMED (NASDAQ:ABMD)

Insider Trades by Quarter for ABIOMED (NASDAQ ABMD)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/30/2017Dorothy E PuhyDirectorSell6,364$179.08$1,139,665.12View SEC Filing  
10/30/2017Michael G HowleyVPSell10,000$178.64$1,786,400.00View SEC Filing  
10/2/2017Andrew J GreenfieldVPSell11,282$169.32$1,910,268.24View SEC Filing  
8/30/2017Eric A Md RoseDirectorSell982$145.17$142,556.94View SEC Filing  
8/24/2017Eric A Md RoseDirectorSell23,018$151.09$3,477,789.62View SEC Filing  
8/15/2017Paul ThomasDirectorSell10,000$154.71$1,547,100.00View SEC Filing  
7/31/2017David M WeberCOOSell16,500$147.63$2,435,895.00View SEC Filing  
5/16/2017Michael G HowleyVPSell18,279$133.56$2,441,343.24View SEC Filing  
5/8/2017David M WeberCOOSell21,250$130.89$2,781,412.50View SEC Filing  
5/8/2017Dorothy E PuhyDirectorSell13,500$131.12$1,770,120.00View SEC Filing  
5/8/2017Michael G HowleyVPSell600$132.84$79,704.00View SEC Filing  
3/17/2017Andrew J GreenfieldVPSell10,000$124.00$1,240,000.00View SEC Filing  
12/13/2016Dorothy E PuhyDirectorSell8,000$120.00$960,000.00View SEC Filing  
11/30/2016Eric A Md RoseDirectorSell8,000$110.81$886,480.00View SEC Filing  
9/22/2016Michael R MinogueCEOSell28,039$127.07$3,562,915.73View SEC Filing  
9/21/2016Michael R MinogueCEOSell5,034$127.07$639,670.38View SEC Filing  
9/19/2016Michael R MinogueCEOSell58,710$127.00$7,456,170.00View SEC Filing  
8/15/2016Dorothy E PuhyDirectorSell5,160$123.94$639,530.40View SEC Filing  
8/10/2016Dorothy E PuhyDirectorSell3,900$122.31$477,009.00View SEC Filing  
8/8/2016Michael G HowleyVPSell17,853$119.20$2,128,077.60View SEC Filing  
8/1/2016Henri A TermeerDirectorSell25,866$118.70$3,070,294.20View SEC Filing  
6/29/2016Michael G HowleyVPSell10,000$106.58$1,065,800.00View SEC Filing  
6/7/2016Andrew J GreenfieldVPSell9,000$104.16$937,440.00View SEC Filing  
5/23/2016David M WeberCOOSell4,342$96.97$421,043.74View SEC Filing  
5/16/2016David M WeberCOOSell5,604$94.56$529,914.24View SEC Filing  
5/6/2016David M WeberCOOSell2,145$93.82$201,243.90View SEC Filing  
5/5/2016David M WeberCOOSell52,000$95.27$4,954,040.00View SEC Filing  
5/5/2016Paul ThomasDirectorSell7,500$95.14$713,550.00View SEC Filing  
4/18/2016Andrew J GreenfieldVPSell10,000$99.10$991,000.00View SEC Filing  
4/13/2016Michael G HowleyVPSell9,800$98.64$966,672.00View SEC Filing  
4/8/2016Michael G HowleyVPSell200$98.80$19,760.00View SEC Filing  
4/1/2016Dorothy E PuhyDirectorSell10,000$95.02$950,200.00View SEC Filing  
3/31/2016Andrew J GreenfieldVPSell15,000$94.11$1,411,650.00View SEC Filing  
3/24/2016David M WeberCOOSell5,235$89.93$470,783.55View SEC Filing  
3/22/2016Andrew J GreenfieldVPSell24,800$89.06$2,208,688.00View SEC Filing  
3/22/2016Dorothy E PuhyDirectorSell10,000$90.30$903,000.00View SEC Filing  
3/21/2016Andrew J GreenfieldVPSell19,572$89.07$1,743,278.04View SEC Filing  
3/10/2016Andrew J GreenfieldVPSell200$89.00$17,800.00View SEC Filing  
3/8/2016David M WeberCOOSell17,521$85.20$1,492,789.20View SEC Filing  
3/8/2016William J BoltSVPSell17,510$85.19$1,491,676.90View SEC Filing  
3/7/2016David M WeberCOOSell8,111$85.21$691,138.31View SEC Filing  
3/7/2016Dorothy E PuhyDirectorSell4,000$85.00$340,000.00View SEC Filing  
3/7/2016William J BoltSVPSell7,987$85.20$680,492.40View SEC Filing  
2/8/2016Dorothy E. PuhyDirectorSell4,000$80.47$321,880.00View SEC Filing  
8/19/2015Michael R. MinogueCEOSell146,800$104.87$15,394,916.00View SEC Filing  
8/17/2015Dorothy E PuhyDirectorSell2,580$103.91$268,087.80View SEC Filing  
8/14/2015Dorothy E PuhyDirectorSell2,580$105.27$271,596.60View SEC Filing  
7/17/2015Michael G HowleyVPSell21,295$70.00$1,490,650.00View SEC Filing  
6/15/2015Andrew J GreenfieldVPSell3,185$65.00$207,025.00View SEC Filing  
5/29/2015Martin P SutterDirectorBuy7,500$60.17$451,275.00View SEC Filing  
5/27/2015David M WeberCOOSell17,968$60.77$1,091,915.36View SEC Filing  
5/12/2015Michael G HowleyVPSell17,353$66.47$1,153,453.91View SEC Filing  
5/7/2015Andrew J GreenfieldVPSell3,500$71.00$248,500.00View SEC Filing  
5/7/2015Robert BowenCFOSell2,372$71.52$169,645.44View SEC Filing  
5/6/2015David M WeberCOOSell1,605$73.72$118,320.60View SEC Filing  
5/6/2015Michael R MinogueCEOSell8,840$73.12$646,380.80View SEC Filing  
5/6/2015William J BoltSVPSell1,750$74.27$129,972.50View SEC Filing  
3/23/2015David M WeberCOOSell3,765$71.08$267,616.20View SEC Filing  
10/31/2014Andrew J GreenfieldVPSell15,000$31.90$478,500.00View SEC Filing  
10/31/2014Michael R MinogueCEOSell164,000$31.14$5,106,960.00View SEC Filing  
7/28/2014Michael R MinogueCEOSell82,383$26.30$2,166,672.90View SEC Filing  
5/27/2014Andrew J GreenfieldVPSell7,026$21.10$148,248.60View SEC Filing  
5/27/2014David M WeberCOOSell10,172$21.11$214,730.92View SEC Filing  
5/27/2014Michael R MinogueCEOSell90,001$21.19$1,907,121.19View SEC Filing  
5/27/2014Robert BowenCFOSell6,820$21.11$143,970.20View SEC Filing  
5/27/2014William J BoltSVPSell8,029$21.10$169,411.90View SEC Filing  
5/15/2014David WeberCOOSell1,425$20.94$29,839.50View SEC Filing  
5/15/2014Michael HowleyVPSell1,267$20.94$26,530.98View SEC Filing  
5/15/2014Michael MinogueCEOSell4,433$20.94$92,827.02View SEC Filing  
5/15/2014William BoltSVPSell1,110$20.94$23,243.40View SEC Filing  
1/10/2014Robert BowenCFOSell37,500$30.00$1,125,000.00View SEC Filing  
9/3/2013David WeberCOOSell6,500$24.00$156,000.00View SEC Filing  
9/3/2013William BoltSVPSell20,000$24.00$480,000.00View SEC Filing  
8/14/2013William BoltSVPSell21,534$23.35$502,818.90View SEC Filing  
8/13/2013David WeberCOOSell4,400$23.00$101,200.00View SEC Filing  
8/13/2013Michael HowleyVPSell8,400$23.00$193,200.00View SEC Filing  
8/5/2013David WeberCOOSell7,100$22.90$162,590.00View SEC Filing  
8/5/2013Michael HowleyVPSell1,600$23.03$36,848.00View SEC Filing  
8/5/2013Robert BowenCFOSell2,235$22.64$50,600.40View SEC Filing  
8/5/2013W Gerald AustenDirectorSell8,000$22.85$182,800.00View SEC Filing  
8/5/2013William BoltSVPSell20,166$22.70$457,768.20View SEC Filing  
7/31/2013Michael R MinogueCEOSell36,500$25.04$913,960.00View SEC Filing  
7/17/2013Michael G HowleyVPSell10,000$24.45$244,500.00View SEC Filing  
7/15/2013Robert BowenCFOSell40,786$23.50$958,471.00View SEC Filing  
7/11/2013Robert BowenCFOSell1,499$23.50$35,226.50View SEC Filing  
6/4/2013David M WeberCOOSell6,519$21.20$138,202.80View SEC Filing  
6/4/2013Michael G HowleyVPSell3,881$21.20$82,277.20View SEC Filing  
6/4/2013Michael R MinogueCEOSell17,667$21.23$375,070.41View SEC Filing  
6/4/2013Robert BowenCFOSell5,298$21.20$112,317.60View SEC Filing  
6/4/2013William J BoltSVPSell4,967$21.20$105,300.40View SEC Filing  
5/29/2013Michael R MinogueCEOSell58,833$21.83$1,284,324.39View SEC Filing  
5/28/2013David M WeberCOOSell6,018$22.18$133,479.24View SEC Filing  
5/28/2013Michael G HowleyVPSell5,476$22.18$121,457.68View SEC Filing  
5/28/2013Robert BowenCFOSell5,102$22.18$113,162.36View SEC Filing  
5/28/2013William J BoltSVPSell4,629$22.18$102,671.22View SEC Filing  
5/23/2013Andrew J GreenfieldVPSell1,666$21.63$36,035.58View SEC Filing  
5/23/2013Michael R MinogueCEOSell5,666$21.62$122,498.92View SEC Filing  
5/17/2013Robert BowenCFOSell2,715$23.50$63,802.50View SEC Filing  
5/9/2013Michael R MinogueCEOSell20,000$21.00$420,000.00View SEC Filing  
5/7/2013Henri A TermeerDirectorBuy100,000$19.86$1,986,000.00View SEC Filing  
2/25/2013Henri A TermeerDirectorBuy100,000$14.98$1,498,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for ABIOMED (NASDAQ ABMD)

Source:
DateHeadline
ETFs with exposure to ABIOMED, Inc. : November 24, 2017ETFs with exposure to ABIOMED, Inc. : November 24, 2017
finance.yahoo.com - November 24 at 3:19 PM
ETFs with exposure to ABIOMED, Inc. : November 13, 2017ETFs with exposure to ABIOMED, Inc. : November 13, 2017
finance.yahoo.com - November 13 at 5:22 PM
Head to Head Review: ABIOMED (ABMD) & IRIDEX Corporation (IRIX)Head to Head Review: ABIOMED (ABMD) & IRIDEX Corporation (IRIX)
www.americanbankingnews.com - November 13 at 7:34 AM
ABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $147.65 MillionABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $147.65 Million
www.americanbankingnews.com - November 10 at 11:12 AM
Industry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy - Investorplace.comIndustry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy - Investorplace.com
investorplace.com - November 9 at 3:21 AM
ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q2, 2018 By the Numbers : November 8, 2017ABIOMED, Inc. :ABMD-US: Earnings Analysis: Q2, 2018 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:14 PM
ABIOMED, Inc. (ABMD) Expected to Post Earnings of $0.50 Per ShareABIOMED, Inc. (ABMD) Expected to Post Earnings of $0.50 Per Share
www.americanbankingnews.com - November 8 at 5:26 AM
ABIOMED, Inc. (ABMD) Upgraded at Zacks Investment ResearchABIOMED, Inc. (ABMD) Upgraded at Zacks Investment Research
www.americanbankingnews.com - November 7 at 9:06 PM
Industry Group Rank Analytics Power Abiomed (ABMD) to Strong BuyIndustry Group Rank Analytics Power Abiomed (ABMD) to Strong Buy
investorplace.com - November 7 at 6:51 PM
De Burlo Group Inc Buys Applied Materials Inc, American Tower Corp, Netflix Inc, Sells C.R. ...De Burlo Group Inc Buys Applied Materials Inc, American Tower Corp, Netflix Inc, Sells C.R. ...
www.nasdaq.com - November 3 at 3:13 PM
ABIOMED, Inc. (ABMD) Stock Rating Reaffirmed by SunTrust Banks, Inc.ABIOMED, Inc. (ABMD) Stock Rating Reaffirmed by SunTrust Banks, Inc.
www.americanbankingnews.com - November 1 at 8:28 PM
ABIOMED, Inc. (ABMD) Director Sells $1,139,665.12 in StockABIOMED, Inc. (ABMD) Director Sells $1,139,665.12 in Stock
www.americanbankingnews.com - November 1 at 5:25 PM
Insider Selling: ABIOMED, Inc. (ABMD) VP Sells 10,000 Shares of StockInsider Selling: ABIOMED, Inc. (ABMD) VP Sells 10,000 Shares of Stock
www.americanbankingnews.com - November 1 at 5:24 PM
Abiomed (ABMD) Looks Good: Stock Adds 7.5% in Session - NasdaqAbiomed (ABMD) Looks Good: Stock Adds 7.5% in Session - Nasdaq
www.nasdaq.com - November 1 at 3:24 PM
Abiomed (ABMD) Looks Good: Stock Adds 7.5% in SessionAbiomed (ABMD) Looks Good: Stock Adds 7.5% in Session
finance.yahoo.com - November 1 at 3:24 PM
ETFs with exposure to ABIOMED, Inc. : November 1, 2017ETFs with exposure to ABIOMED, Inc. : November 1, 2017
finance.yahoo.com - November 1 at 3:24 PM
ABIOMED, Inc. (ABMD) Given Average Recommendation of "Buy" by BrokeragesABIOMED, Inc. (ABMD) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - November 1 at 10:18 AM
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2 - NasdaqAbiomed (ABMD) Earnings and Revenues Beat Estimates in Q2 - Nasdaq
www.nasdaq.com - October 30 at 3:25 PM
Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2Abiomed (ABMD) Earnings and Revenues Beat Estimates in Q2
finance.yahoo.com - October 30 at 3:24 PM
FY2018 Earnings Estimate for ABIOMED, Inc. Issued By William Blair (ABMD)FY2018 Earnings Estimate for ABIOMED, Inc. Issued By William Blair (ABMD)
www.americanbankingnews.com - October 30 at 10:57 AM
Q3 2018 EPS Estimates for ABIOMED, Inc. Increased by Analyst (ABMD)Q3 2018 EPS Estimates for ABIOMED, Inc. Increased by Analyst (ABMD)
www.americanbankingnews.com - October 30 at 9:43 AM
Equities Analysts Offer Predictions for ABIOMED, Inc.s Q3 2018 Earnings (ABMD)Equities Analysts Offer Predictions for ABIOMED, Inc.'s Q3 2018 Earnings (ABMD)
www.americanbankingnews.com - October 30 at 9:42 AM
ABIOMEDs (ABMD) CEO Mike Minogue on Q2 2018 Results - Earnings Call TranscriptABIOMED's (ABMD) CEO Mike Minogue on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - October 28 at 3:54 PM
Abiomed Announces First Patient Treated with Impella® in Japan - GlobeNewswire (press release)Abiomed Announces First Patient Treated with Impella® in Japan - GlobeNewswire (press release)
globenewswire.com - October 27 at 10:40 PM
BRIEF-Abiomed Q2 earnings per share $0.54BRIEF-Abiomed Q2 earnings per share $0.54
www.businessinsider.com - October 27 at 5:31 PM
Company News For Oct 27, 2017Company News For Oct 27, 2017
finance.yahoo.com - October 27 at 5:31 PM
Abiomed, Incs Revenue and Profits Soar Yet AgainAbiomed, Inc's Revenue and Profits Soar Yet Again
finance.yahoo.com - October 26 at 8:12 PM
Edited Transcript of ABMD earnings conference call or presentation 26-Oct-17 12:00pm GMTEdited Transcript of ABMD earnings conference call or presentation 26-Oct-17 12:00pm GMT
finance.yahoo.com - October 26 at 8:12 PM
Abiomed, Inc's Revenue and Profits Soar Yet AgainAbiomed, Inc's Revenue and Profits Soar Yet Again
finance.yahoo.com - October 26 at 8:12 PM
ABIOMED, Inc. (ABMD) PT Raised to $200.00 at Piper Jaffray CompaniesABIOMED, Inc. (ABMD) PT Raised to $200.00 at Piper Jaffray Companies
www.americanbankingnews.com - October 26 at 7:24 PM
ABIOMED, Inc. (ABMD) Releases  Earnings Results, Beats Estimates By $0.16 EPSABIOMED, Inc. (ABMD) Releases Earnings Results, Beats Estimates By $0.16 EPS
www.americanbankingnews.com - October 26 at 2:38 PM
Abiomed (ABMD) Reports First Patient Treated with Impella in JapanAbiomed (ABMD) Reports First Patient Treated with Impella in Japan
www.streetinsider.com - October 26 at 11:39 AM
Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%Abiomed Announces Q2 FY 2018 Revenue of $132.8 Million, Up 29% and Record U.S. Patient Utilization, Up 33%
finance.yahoo.com - October 26 at 11:38 AM
Abiomed Announces First Patient Treated with Impella® in JapanAbiomed Announces First Patient Treated with Impella® in Japan
finance.yahoo.com - October 26 at 11:38 AM
Abiomed beats Street 2Q forecastsAbiomed beats Street 2Q forecasts
finance.yahoo.com - October 26 at 11:38 AM
ABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $130.80 MillionABIOMED, Inc. (ABMD) Expected to Announce Quarterly Sales of $130.80 Million
www.americanbankingnews.com - October 21 at 6:58 AM
Abiomeds Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 PresentationsAbiomed's Impella® Technology that Enables Heart Recovery Showcased at TCT 2017 With More Than 30 Presentations
finance.yahoo.com - October 19 at 8:31 PM
Zacks: Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Earnings of $0.37 Per ShareZacks: Analysts Anticipate ABIOMED, Inc. (ABMD) Will Post Earnings of $0.37 Per Share
www.americanbankingnews.com - October 19 at 8:18 AM
Analyzing ABIOMED (ABMD) & ABAXIS (ABAX)Analyzing ABIOMED (ABMD) & ABAXIS (ABAX)
www.americanbankingnews.com - October 18 at 8:18 PM
ABIOMED Reaches Analyst Target Price - NasdaqABIOMED Reaches Analyst Target Price - Nasdaq
www.nasdaq.com - October 18 at 3:42 PM
ABIOMED, Inc. (ABMD) Set to Announce Earnings on WednesdayABIOMED, Inc. (ABMD) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - October 18 at 2:38 AM
ABIOMED, Inc. (ABMD) Downgraded by BTIG Research to "Neutral"ABIOMED, Inc. (ABMD) Downgraded by BTIG Research to "Neutral"
www.americanbankingnews.com - October 16 at 8:20 AM
Financial Analysis: ABIOMED (ABMD) & Its PeersFinancial Analysis: ABIOMED (ABMD) & Its Peers
www.americanbankingnews.com - October 15 at 2:10 AM
ABIOMED, Inc. (ABMD) Receives "Outperform" Rating from Leerink SwannABIOMED, Inc. (ABMD) Receives "Outperform" Rating from Leerink Swann
www.americanbankingnews.com - October 15 at 12:34 AM
Smith & Nephew Shows Improved Relative Price Performance; Still Shy Of BenchmarkSmith & Nephew Shows Improved Relative Price Performance; Still Shy Of Benchmark
finance.yahoo.com - October 11 at 3:35 PM
ABIOMED, Inc. (ABMD) Downgraded by Zacks Investment ResearchABIOMED, Inc. (ABMD) Downgraded by Zacks Investment Research
www.americanbankingnews.com - October 10 at 11:26 PM
Abiomed Second Quarter Fiscal 2018 Earnings and Conference Call NotificationAbiomed Second Quarter Fiscal 2018 Earnings and Conference Call Notification
finance.yahoo.com - October 10 at 3:30 PM
Head to Head Survey: ABIOMED (ABMD) vs. Hansen Medical (HNSN)Head to Head Survey: ABIOMED (ABMD) vs. Hansen Medical (HNSN)
www.americanbankingnews.com - October 9 at 10:14 AM
ABIOMED, Inc. (ABMD) Receives Average Rating of "Buy" from BrokeragesABIOMED, Inc. (ABMD) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - October 7 at 8:50 AM
Contrasting ABIOMED (ABMD) & The CompetitionContrasting ABIOMED (ABMD) & The Competition
www.americanbankingnews.com - October 4 at 8:30 PM

Social Media

Financials

Chart

ABIOMED (NASDAQ ABMD) Chart for Saturday, November, 25, 2017
Loading chart…

This page was last updated on 11/25/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.